Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Access Biotechnology
New York, New York, United States
- Ownership
- Private
- Employees
- ~51
- Development stage
- Other
01
Overview
Access Biotechnology is an investment arm focused on backing innovative biotechnology companies developing transformative therapies across a broad range of modalities and diseases. They invest from discovery-stage platforms to late-stage clinical programs and have contributed to both early- and late-stage financings for companies that have progressed to acquisition or advanced clinical development.[1][3][5]
- Modalities
- Small moleculeBiologicMonoclonal antibodyAntibody-drug conjugate
- Industry
- Investors
02
Partnerships
Halda TherapeuticsPandion TherapeuticsUpstream BioAreteia TherapeuticsMatchpoint TherapeuticsHemab TherapeuticsZura Bio
Beyond the preview
Go deeper on Access Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Access Biotechnology.